Academic Journal
Q1The Lancet Healthy Longevity
About The Lancet Healthy Longevity
The Lancet Healthy Longevity is a scholarly journal published by Elsevier Ltd. SCImago 2025 places it in Q1 with an SJR of 5.433 and an H-index of 60.
Its listed coverage is 2020-2026 and its research categories include Family Practice (Q1); Geriatrics and Gerontology (Q1); Health (social science) (Q1); Psychiatry and Mental Health (Q1). The 2025 dataset reports 131 documents and 3769 citations across the latest three-year reporting window.
The Lancet Healthy Longevity: Advancing Global Understanding of Aging and Elder Care
The Lancet Healthy Longevity is a leading peer-reviewed medical journal dedicated to promoting research, innovation, and policy insights focused on the health and well-being of aging populations worldwide. Launched as part of the prestigious Lancet family of journals, it offers a high-impact platform for scientific findings related to geriatric medicine, age-related diseases, and strategies for healthy aging.
As global demographics shift, the number of individuals aged 60 and over continues to rise dramatically. According to the World Health Organization, by 2050, the global population aged 60 years and older is expected to double, reaching 2.1 billion. This demographic transformation brings both challenges and opportunities in the fields of healthcare, social support, and policy-making. The Lancet Healthy Longevity plays a crucial role in addressing these changes by publishing groundbreaking research that informs clinical practice and public health strategy.
What Does The Lancet Healthy Longevity Cover?
The journal covers a wide spectrum of topics related to aging and longevity, including but not limited to:
-
Geriatric medicine and primary care
-
Age-related chronic diseases such as dementia, cardiovascular conditions, and osteoporosis
-
Palliative care and end-of-life planning
-
Public health and preventive strategies
-
Mental health in older adults
-
Socioeconomic and policy implications of aging populations
-
Technological innovations to support aging in place
It publishes a variety of article types, including original research, reviews, commentaries, and editorials, all rigorously peer-reviewed to maintain the highest standards of scientific integrity.
Why Is The Lancet Healthy Longevity Important?
The Lancet Healthy Longevity is more than just a journal—it’s a catalyst for change. By disseminating evidence-based knowledge, it empowers clinicians, researchers, and policy makers to create better systems of care for aging populations. The journal promotes interdisciplinary collaboration, integrating perspectives from medicine, public health, social sciences, and technology to provide comprehensive solutions for the aging global population.
Furthermore, the journal's commitment to open access ensures that its findings are accessible to a global audience, helping to bridge gaps in knowledge and healthcare between high-income and low-to-middle-income countries.
Relevance to Healthcare Professionals and Researchers
Healthcare providers, gerontologists, and researchers rely on The Lancet Healthy Longevity to stay current with the latest developments in elder care and aging research. With its high impact factor and affiliation with The Lancet family, the journal offers a trusted source of information that influences clinical guidelines and global health policies.
Journal Metrics
Metrics can change by reporting year. Verify time-sensitive values with the publisher or indexing service.
Aims & Scope
Understanding the Scope of The Lancet Healthy Longevity: Advancing Aging Research and Care
The Lancet Healthy Longevity is a premier, peer-reviewed medical journal that focuses on the challenges and innovations surrounding aging, geriatric care, and the pursuit of healthy longevity. As a key title in the globally respected Lancet family of journals, it addresses the multidimensional aspects of aging and brings together cutting-edge research, clinical practice, and public health insights to promote healthy aging across the lifespan.
A Global Platform for Aging Research
The scope of The Lancet Healthy Longevity is broad yet targeted, emphasizing interdisciplinary research that advances understanding and improves outcomes for aging populations worldwide. The journal publishes original research articles, systematic reviews, policy papers, and commentaries that explore biological, clinical, social, and environmental factors influencing aging and longevity.
With an international readership that includes clinicians, researchers, public health professionals, and policymakers, the journal serves as a critical platform for sharing evidence-based strategies to enhance the quality of life for older adults. Topics include age-related diseases, multimorbidity, frailty, cognitive decline, longevity medicine, social determinants of aging, and innovations in elder care.
Bridging Clinical Practice and Public Health
One of the defining features of The Lancet Healthy Longevity is its commitment to bridging the gap between clinical care and public health. By integrating scientific discovery with practical applications, the journal supports a holistic approach to aging. Its articles often focus on preventive measures, healthcare policy, and interventions that reduce health disparities among older adults.
Key research published in the journal often examines the impact of healthcare systems, socioeconomic status, and environmental factors on aging. It also sheds light on how digital health tools, telemedicine, and personalized medicine can optimize care for older individuals in diverse settings, including low- and middle-income countries.
Impact and Influence in Geriatric Science
The Lancet Healthy Longevity plays a crucial role in influencing global discussions about aging. By publishing high-impact studies and expert commentaries, it contributes to shaping healthcare policy and promoting innovations that respond to the demographic shifts of aging populations. The journal is committed to open access, ensuring that its findings are widely accessible to stakeholders around the world.
Its rigorous peer-review process and high editorial standards maintain the integrity and scientific excellence associated with the Lancet brand. The journal also prioritizes diversity and inclusion in research, promoting studies that reflect the experiences and needs of aging individuals from various backgrounds and regions.
Recent Research Articles
Latest publications matched automatically by ISSN.
Mode of anaesthesia for hip fracture surgery: is it time to put the question to sleep?
Iain Moppett, Cliff Shelton
2026-09 · DOI: 10.1016/j.lanhl.2026.100909Effectiveness of digital health technologies for post-discharge follow-up and management in older adults: a systematic review
Harmehr Sekhon, Ariane Lajoie, Sarah Aly, Sasha Elbaz et al.
2026-09 · DOI: 10.1016/j.lanhl.2026.100885Spinal versus general anaesthesia and serious complications in older patients undergoing hip fracture surgery in Germany: a multicentre randomised clinical trial
Ana Kowark, Stefanie Schoenen, Rene Schmidt, Haris Zubanovic et al.
2026-09 · DOI: 10.1016/j.lanhl.2026.100891Ageing Well for Indigenous Peoples: Closing the Health Equity Gap
The Lancet Healthy Longevity
2026-09 · DOI: 10.1016/j.lanhl.2026.100912Deprescribing trials need a rationale-first framework before choosing trial design
Catherine S Hwang, Kenneth S Boockvar, Michael A Steinman
2026-08 · DOI: 10.1016/j.lanhl.2026.100893Reframing sarcopenia as a disease of the ageing motor system
Lucas B R Orssatto, W David Arnold, Luigi Ferrucci, Marco V Narici et al.
2026-08 · DOI: 10.1016/j.lanhl.2026.100898Deprescribing trials need a rationale-first framework before choosing trial design
Lorenz Roger Van der Linden
2026-08 · DOI: 10.1016/j.lanhl.2026.100892Community-acquired pneumonia in adults: acute and long-term complications
Jodie Chalmers, Krishan Bansal, Rachel Scott, Fergus Hamilton et al.
2026-08 · DOI: 10.1016/j.lanhl.2026.100872Highlights of IAGG 2026
Philippa K Harris
2026-08 · DOI: 10.1016/j.lanhl.2026.100902Frailty, clinical outcomes, and treatment effects of a care bundle in acute intracerebral haemorrhage: a post-hoc analysis of the INTERACT3 trial
Tao Liu, Linan Chen, Yang Liu, Zhihao Zhao et al.
2026-08 · DOI: 10.1016/j.lanhl.2026.100889Metformin added to lifestyle intervention for physical function in older adults with obesity (DEMFOS trial): a randomised controlled trial
Maria Liza Duremdes Nava, Viola Viola, Marlene Aguilar, Mon S Bryant et al.
2026-07 · DOI: 10.1016/j.lanhl.2026.100883Falls resilience framework: advancing from risk reduction to resilience building in older adults
Deepak K Ravi, Jeffrey M Hausdorff, Heather E Whitson, Nathalie van der Velde et al.
2026-07 · DOI: 10.1016/j.lanhl.2026.100880Discontinuation of statins for primary prevention of atherosclerotic cardiovascular disease in adults aged 75 years or older (SAGA/SITE): a multicentre, open-label, pragmatic, non-inferiority randomised trial
Fabrice Bonnet, Pierre Poulizac, Nicolas Rousselot, Thierry Couffinhal et al.
2026-07 · DOI: 10.1016/j.lanhl.2026.100884Effectiveness of dyadic interventions in improving outcomes for adults with multiple long-term conditions or frailty and their informal carers: a systematic review
Stella Arakelyan, Daniela Lillekroken, Mozhu Ding, Michaela Gilarova et al.
2026-07 · DOI: 10.1016/j.lanhl.2026.100875Ending preventable heat-related deaths among older adults
The Lancet Healthy Longevity
2026-07 · DOI: 10.1016/j.lanhl.2026.100901Revisiting relationships between APOE and dementia incidence in people aged 90 years and older
Olusegun Baiyewu, Olufisayo Elugbadebo
2026-07 · DOI: 10.1016/j.lanhl.2026.100896Cognitive behavioural therapy for insomnia and epigenetic ageing: secondary analysis from a randomised controlled trial
Judith E Carroll, Cynthia D Kusters, Hash Brown Taha, Richard Olmstead et al.
2026-07 · DOI: 10.1016/j.lanhl.2026.100861Statin discontinuation in older adults: changing the conversation, not the default
Shefa Arya Nezhad, Parvaneh Rastgou, Michael G Nanna
2026-07 · DOI: 10.1016/j.lanhl.2026.100888Adjunctive metformin for obesity and frailty in older people—puncturing inflated expectations?
Miles D Witham, Claire McDonald
2026-07 · DOI: 10.1016/j.lanhl.2026.100890Incidence of dementia after age 90 years and association with APOE genotype, race, and sex in the USA: the LifeAfter90 prospective cohort study
Hilary L Colbeth, Maria M Corrada, Dan Mungas, Paola Gilsanz et al.
2026-07 · DOI: 10.1016/j.lanhl.2026.100882Reviews
Community Reviews
Version History
April 23, 2025 at 3:01 am
April 23, 2025